Rationale and design of the Glitazones and the Endothelium (GATE) study: Evaluation of rosiglitazone on endothelial function in patients with diabetes

Canadian Journal of Cardiology

Volumn 20, Issue 14, 2004, Pages 1449-1453

  Hubacek, Jaroslav ^a   Verma, Subodh ^a,b,c   Shewchuk, Lana ^a   Ross, Stuart J ^a   Edwards, Alun ^a   Anderson, Todd J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Diabetes mellitus; Drugs; Endothelium

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCHOLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; VERAPAMIL;

ADD ON THERAPY; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TARGETING; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

ADMINISTRATION, ORAL; ADULT; AGED; ALBERTA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 12144266325     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002;105:546-9.
2. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003;8:71-86.
3. Bonetti PO, Lilach OL, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-75.
4. Verma S, Anderson TJ, Mather KJ. Insulin action in the vasculature: Physiology and pathophysiology. J Vasc Res 2001;38:415-22.
5. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-50.
6. Consoli A, Nurihan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989;38:550-7.
7. Stumvoll M, Nurjhan N, Perriello G. Metabolic effects of metformin in NIDDM. N Engl J Med 1995;333:550-4.
8. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-67.
9. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
10. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
11. Lehmann JM, Moore LB, Smith-Oliver TA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-6.
12. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
13. Smith SA, Cawthorne MA, Coyle PJ, et al. BRL 49653C normalizes glycemic control in Zucker fatty fa/fa rats by improving hepatic and peripheral tissue sensitivity to insulin. Diabetologia 1993;36(Suppl 1):A184. (Abst)
14. Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: Critical appraisal for the clinician. Circulation 2003;107:1350-4.
15. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:717-26.
16. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-905.
17. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993;265:R726-32.
18. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-20.
19. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura J. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6.
20. Naderali EK, Pickavance LC, Wilding JP, Doyle PJ, Williams G. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. Eur J Pharmacol 2001;416:133-9.
21. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998;41:569-76.
22. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000;7:159-63.
23. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000;283:1695-702.
24. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hemekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
25. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
26. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
27. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
28. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
29. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
30. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
31. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000;321:199-204.
32. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
33. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.
34. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-92.
35. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
36. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-90.
37. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
38. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
39. Verma S, Wang CH, Weisel RD, et al. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: Reversal with rosiglitazone. J Mol Cell Cardiol 2003;35:417-9.
40. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.